Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6425856 | 0.94 | PTGS1 (0.61) | PTGS2PTGS1NPSR1LMNACYP1A2 | |
| SCHEMBL6426741 | 0.92 | PTGS2 (0.52) | PTGS2PTGS1NPSR1LMNACYP1A2 | |
| SCHEMBL6426557 | 0.88 | PTGS2 (0.56) | PTGS2PTGS1NPSR1LMNACYP1A2 | |
| SCHEMBL6423697 | 0.87 | PTGS2 (0.54) | PTGS2PTGS1NPSR1LMNACYP1A2 | |
| SCHEMBL6424085 | 0.84 | PTGS2 (0.50) | PTGS2PTGS1NPSR1LMNACYP1A2 | |
| SCHEMBL6423527 | 0.84 | PTGS2 (0.57) | PTGS2PTGS1NPSR1LMNACYP1A2 | |
| SCHEMBL6423626 | 0.82 | AKR1C3 (0.43) | PTGS2PTGS1PPARGABCB1 | |
| SCHEMBL6425916 | 0.82 | PTGS2 (0.61) | PTGS2PTGS1NPSR1PPARGABCB1 | |
| SCHEMBL6426921 | 0.82 | NPSR1 (0.38) | PTGS2PTGS1NPSR1LMNACYP1A2 | |
| SCHEMBL6425733 | 0.82 | PTGS2 (0.56) | PTGS2PTGS1NPSR1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | PTGS2 4/4885PTGS1 7/4885NPSR1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.